Abstract
Background: Pathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk of aggressive prostate cancer (PC). Our objectives were to determine the prevalence of pathogenic germline mutations in men with low-risk PC on active surveillance, and assess whether pathogenic germline mutations associate with grade reclassification or adverse pathology, recurrence, or metastases, in men treated after initial surveillance. Methods: Men prospectively enrolled in the Canary Prostate Active Surveillance Study (PASS) were retrospectively sampled for the study. Germline DNA was sequenced utilizing a hereditary cancer gene panel. Mutations were classified according to the American College of Clinical Genetics and Genomics' guidelines. The association of pathogenic germline mutations with grade reclassification and adverse characteristics was evaluated by weighted Cox proportional hazards modeling and conditional logistic regression, respectively. Results: Overall, 29 of 437 (6.6%) study participants harbored a pathogenic germline mutation of which 19 occurred in a gene involved in DNA repair (4.3%). Eight participants (1.8%) had pathogenic germline mutations in three genes associated with aggressive PC: ATM, BRCA1, and BRCA2. The presence of pathogenic germline mutations in DNA repair genes did not associate with adverse characteristics (univariate analysis HR = 0.87, 95% CI: 0.36–2.06, p = 0.7). The carrier rates of pathogenic germline mutations in ATM, BRCA1, and BRCA2did not differ in men with or without grade reclassification (1.9% vs. 1.8%). Conclusion: The frequency of pathogenic germline mutations in penetrant cancer predisposition genes is extremely low in men with PC undergoing active surveillance and pathogenic germline mutations had no apparent association with grade reclassification or adverse characteristics.
| Original language | English |
|---|---|
| Pages (from-to) | 4332-4340 |
| Number of pages | 9 |
| Journal | Cancer Medicine |
| Volume | 11 |
| Issue number | 22 |
| DOIs | |
| State | Published - Nov 2022 |
Bibliographical note
Publisher Copyright:© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Funding
This study was supported by the Canary Foundation, NIH awards CA097186, U01 CA224255, and P30 CA015704, CDMPR awards, PC171001, PC170503, PC170510, PC170503P2, PC200262P1, the Prostate Cancer Foundation, and the Institute for Prostate Cancer Research. Funding information
| Funders | Funder number |
|---|---|
| Institute for Prostate Cancer Research | |
| National Institutes of Health (NIH) | PC171001, PC200262P1, PC170503P2, CA097186, PC170510, U01 CA224255 |
| National Childhood Cancer Registry – National Cancer Institute | P30CA015704 |
| Prostate Cancer Foundation | |
| Canary Foundation |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- active surveillance
- adverse pathology
- germline mutations
- prostate cancer
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver